A new report conducted by Patient View, a patient insight organization, explores the corporate reputation of the pharmacy industry from the perspective of cancer patients.
For the report, researchers polled 251 cancer patient groups worldwide on their perceptions of 26 pharmaceutical companies between November 2016 and early-February 2017.
Here are five survey findings.
- Nearly half (49 percent) of cancer patient groups said the drug industry had an "excellent" or "good" corporate reputation in 2016.
- Respondents ranked the drug industry third out of eight healthcare industry sectors for having an "excellent" or "good reputation."
- Nearly three-fourths of cancer patient groups said the drug industry was "excellent" or "good" at producing innovative and high quality cancer products.
- Only 7 percent of respondents said the pharmaceutical industry was "excellent" or "good" at fair product pricing.
- Cancer patient groups were most familiar with Novartis (79 percent), followed by Roche (75 percent) and Pfizer (72 percent).
To view the full report, click here.
More articles on supply chain:
7 drugmakers in the headlines
4 ways hospitals can lower inpatient drug costs
6 must-reads for supply chain leaders this week